Prof.Dr.med. ID: 6488383

Katja Weisel

graph of relations

Publications

  1. The BCL2 E17 and SP66 antibodies discriminate 2 immunophenotypically and genetically distinct subgroups of conventionally BCL2-"negative" grade 1/2 follicular lymphomas

    Adam, P., Baumann, R., Schmidt, J., Bettio, S., Weisel, K., Bonzheim, I., Fend, F. & Quintanilla-Martínez, L., 09.2013, In: HUM PATHOL. 44, 9, p. 1817-26 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  2. Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma

    Auel, B., Goldschmidt, H., Geer, T., Moehler, T. M., Platzbecker, U., Naumann, R., Blau, I., Hänel, M., Knauf, W., Nückel, H., Salwender, H-J., Scheid, C., Weisel, K., Gorschlüter, M., Glasmacher, A., Schmidt-Wolf, I. G. H. & German Refractory Myeloma Study Group, 06.2012, In: INDIAN J HEMATOL BLO. 28, 2, p. 67-76 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  3. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

    Avet-Loiseau, H., San-Miguel, J., Casneuf, T., Iida, S., Lonial, S., Usmani, S. Z., Spencer, A., Moreau, P., Plesner, T., Weisel, K., Ukropec, J., Chiu, C., Trivedi, S., Amin, H., Krevvata, M., Ramaswami, P., Qin, X., Qi, M., Sun, S., Qi, M., Kobos, R. & Bahlis, N. J., 01.04.2021, In: J CLIN ONCOL. 39, 10, p. 1139-1149 11 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  4. Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients

    Avivi, I., Vesole, D. H., Davila-Valls, J., Usnarska-Zubkiewicz, L., Olszewska-Szopa, M., Milunovic, V., Baumert, B., Osękowska, B., Kopińska, A., Gentile, M., Puertas-Martinez, B., Robak, P., Crusoe, E., Rodriguez-Lobato, L. G., Gajewska, M., Varga, G., Delforge, M., Cohen, Y., Gozzetti, A., Pena, C., Shustik, C., Mikala, G., Zalac, K., Alexander, H. D., Barth, P., Weisel, K., Martínez-López, J., Waszczuk-Gajda, A., Krzystański, M. & Jurczyszyn, A., 01.09.2023, In: CANCERS. 15, 17, 4359.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  5. The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma

    Awwad, M. H. S., Kriegsmann, K., Plaumann, J., Benn, M., Hillengass, J., Raab, M. S., Bertsch, U., Munder, M., Weisel, K., Salwender, H. J., Hänel, M., Fenk, R., Dürig, J., Müller-Tidow, C., Goldschmidt, H. & Hundemer, M., 2018, In: ONCOIMMUNOLOGY. 7, 10, p. e1486356

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  6. Selective elimination of immunosuppressive T cells in patients with multiple myeloma

    Awwad, M. H. S., Mahmoud, A., Bruns, H., Echchannaoui, H., Kriegsmann, K., Lutz, R., Raab, M. S., Bertsch, U., Munder, M., Jauch, A., Weisel, K., Maier, B., Weinhold, N., Salwender, H. J., Eckstein, V., Hänel, M., Fenk, R., Dürig, J., Brors, B., Benner, A., Müller-Tidow, C., Goldschmidt, H. & Hundemer, M., 09.2021, In: LEUKEMIA. 35, 9, p. 2602-2615 14 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  7. A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens: entity-specific dividing lines and "pan-leukemia" antigens

    Backert, L., Kowalewski, D. J., Walz, S., Schuster, H., Berlin, C., Neidert, M. C., Schemionek, M., Brümmendorf, T. H., Vucinic, V., Niederwieser, D., Kanz, L., Salih, H. R., Kohlbacher, O., Weisel, K., Rammensee, H-G., Stevanovic, S. & Walz, J. S., 04.07.2017, In: ONCOTARGET. 8, 27, p. 43915-43924 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  8. Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE

    Baertsch, M-A., Schlenzka, J., Lisenko, K., Krzykalla, J., Becker, N., Weisel, K., Noppeney, R., Martin, H., Lindemann, H. W., Haenel, M., Nogai, A., Scheid, C., Salwender, H., Fenk, R., Graeven, U., Reimer, P., Schmidt-Hieber, M., Goerner, M., Schmidt-Wolf, I. G. H., Klein, S., Ho, A. D., Goldschmidt, H. & Wuchter, P., 07.2017, In: EUR J HAEMATOL. 99, 1, p. 42-50 9 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  9. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma

    Baertsch, M-A., Schlenzka, J., Mai, E. K., Merz, M., Hillengaß, J., Raab, M. S., Hose, D., Wuchter, P., Ho, A. D., Jauch, A., Hielscher, T., Kunz, C., Luntz, S., Klein, S., Schmidt-Wolf, I. G. H., Goerner, M., Schmidt-Hieber, M., Reimer, P., Graeven, U., Fenk, R., Salwender, H., Scheid, C., Nogai, A., Haenel, M., Lindemann, H. W., Martin, H., Noppeney, R., Weisel, K. & Goldschmidt, H., 25.04.2016, In: BMC CANCER. 16, p. 290

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  10. Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

    Baertsch, M-A., Mai, E. K., Hielscher, T., Bertsch, U., Salwender, H. J., Munder, M., Fuhrmann, S., Dührsen, U., Brossart, P., Neben, K., Schlenzka, J., Kunz, C., Raab, M. S., Hillengaß, J., Jauch, A., Seckinger, A., Hose, D., Luntz, S., Sonneveld, P., Lokhorst, H., Martin, H., Goerner, M., Hoffmann, M., Lindemann, H-W., Bernhard, H., Blau, I. W., Scheid, C., Besemer, B., Weisel, K. C., Hänel, M., Dürig, J., Goldschmidt, H. & German-speaking Myeloma Multicenter Group (GMMG), 07.01.2021, In: BLOOD CANCER J. 11, 1, p. 1

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  11. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

    Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., Banos, A., Tiab, M., Delforge, M., Cavenagh, J., Geraldes, C., Lee, J-J., Chen, C., Oriol, A., de la Rubia, J., Qiu, L., White, D. J., Binder, D., Anderson, K., Fermand, J-P., Moreau, P., Attal, M., Knight, R., Chen, G., Van Oostendorp, J., Jacques, C., Ervin-Haynes, A., Avet-Loiseau, H., Hulin, C., Facon, T. & FIRST Trial Team, 04.09.2014, In: NEW ENGL J MED. 371, 10, p. 906-17 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  12. Improved Follow-Up and Response Monitoring of Thoracic Cage Involvement in Multiple Myeloma Using a Novel CT Postprocessing Software: The Lessons We Learned

    Bier, G., Mustafa, D. F., Kloth, C., Weisel, K., Ditt, H., Nikolaou, K. & Horger, M., 01.2016, In: AM J ROENTGENOL. 206, 1, p. 57-63 7 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  13. Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma

    Bilich, T., Nelde, A., Bauer, J., Walz, S., Roerden, M., Salih, H. R., Weisel, K., Besemer, B., Marcu, A., Lübke, M., Schuhmacher, J., Neidert, M. C., Rammensee, H-G., Stevanović, S. & Walz, J. S., 28.02.2020, In: BLOOD CANCER J. 10, 2, p. 24

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  14. Severe psychotic disorder and agranulocytosis--a therapeutic dilemma

    Borbé, R., Weisel, K., Sachs, U. J. H. & Steinert, T., 11.2009, In: PHARMACOPSYCHIATRY. 42, 6, p. 284-5 2 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  15. Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma

    Brauneck, F., Weimer, P., Schulze zur Wiesch, J., Weisel, K. C., Leypoldt, L. B., Vohwinkel, G., Fritzsche, B., Bokemeyer, C., Wellbrock, J. & Fiedler, W., 08.11.2021, In: FRONT MED-LAUSANNE. 8, p. 763773 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  16. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA

    Cavo, M., San-Miguel, J. F. F., Usmani, S. Z., Weisel, K. C., Dimopoulos, M. A. A., Avet-Loiseau, H., Paiva, B., Bahlis, N. J., Plesner, T., Hungria, V. T. D. M., Moreau, P., Mateos, M. V., Perrot, A., Iida, S., Facon, T., Kumar, S. K., van de Donk, N. W. C. J., Sonneveld, P., Spencer, A., Krevvata, M., Heuck, C., Wang, J., Ukropec, J., Kobos, R., Sun, S., Qi, M. & Munshi, N. C., 10.02.2022, In: BLOOD. 139, 6, p. 835-844 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  17. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma

    Chari, A., Vogl, D. T., Gavriatopoulou, M., Nooka, A. K., Yee, A. J., Huff, C. A., Moreau, P., Dingli, D., Cole, C., Lonial, S., Dimopoulos, M., Stewart, A. K., Richter, J., Vij, R., Tuchman, S., Raab, M. S., Weisel, K. C., Delforge, M., Cornell, R. F., Kaminetzky, D., Hoffman, J. E., Costa, L. J., Parker, T. L., Levy, M., Schreder, M., Meuleman, N., Frenzel, L., Mohty, M., Choquet, S., Schiller, G., Comenzo, R. L., Engelhardt, M., Illmer, T., Vlummens, P., Doyen, C., Facon, T., Karlin, L., Perrot, A., Podar, K., Kauffman, M. G., Shacham, S., Li, L., Tang, S., Picklesimer, C., Saint-Martin, J-R., Crochiere, M., Chang, H., Parekh, S., Landesman, Y., Shah, J., Richardson, P. G. & Jagannath, S., 22.08.2019, In: NEW ENGL J MED. 381, 8, p. 727-738 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  18. Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset

    Chari, A., Samur, M. K., Martinez-Lopez, J., Cook, G., Biran, N., Yong, K. L., Hungria, V. T. D. M., Engelhardt, M., Gay, F., Garcia-Feria, A., Oliva, S., Oostvogels, R., Gozzetti, A., Rosenbaum, C. A., Kumar, S. K., Stadtmauer, E., Einsele, H., Beksac, M., Weisel, K. C., Anderson, K. C., Mateos, M-V., Moreau, P., San Miguel, J., Munshi, N. C. & Avet-Loiseau, H., 06.11.2020, In: BLOOD.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  19. Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy

    Chari, A., Munder, M., Weisel, K., Jenner, M., Bygrave, C., Petrucci, M. T., Boccadoro, M., Cavo, M., van de Donk, N. W. C. J., Turgut, M., Demirkan, F., Karadogan, I., Libby, E., Kleiman, R., Kuppens, S., Bandekar, R., Neff, T., Heuck, C., Qi, M., Clemens, P. L. & Goldschmidt, H., 02.2021, In: ADV THER. 38, 2, p. 1328-1341 14 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  20. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

    Chng, W-J., Goldschmidt, H., Dimopoulos, M. A., Moreau, P., Joshua, D., Palumbo, A., Facon, T., Ludwig, H., Pour, L., Niesvizky, R., Oriol, A., Rosiñol, L., Suvorov, A., Gaidano, G., Pika, T., Weisel, K., Goranova-Marinova, V., Gillenwater, H. H., Mohamed, N., Feng, S., Aggarwal, S. & Hájek, R., 06.2017, In: LEUKEMIA. 31, 6, p. 1368-1374 7 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  21. Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma

    Cope, S., Toor, K., Popoff, E., Fonseca, R., Landgren, O., Mateos, M-V., Weisel, K. & Jansen, J. P., 04.2020, In: VALUE HEALTH. 23, 4, p. 441-450 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  22. Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma

    Costa, L. J., Hari, P., Berdeja, J. G., De Stefano, V., Gay, F., Hooper, B., Bartlett, M., Haltner, A., Rosta, E., Kumar, S., Martin, T., Mateos, M-V., Moreau, P., Usmani, S. Z., Olyslager, Y., Schecter, J. M., Roccia, T., Garrett, A., Lee, S., Nesheiwat, T., Pacaud, L., Zhou, C., Samjoo, I. A., Lin, Y., Diels, J., Valluri, S. & Weisel, K., 10.2022, In: CURR MED RES OPIN. 38, 10, p. 1759-1767 9 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  23. INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma

    Costello, C., Davies, F. E., Cook, G., Vela-Ojeda, J., Omel, J., Rifkin, R. M., Berdeja, J., Puig, N., Usmani, S. Z., Weisel, K., Zonder, J. A., Terpos, E., Spencer, A., Leleu, X., Boccadoro, M., Thompson, M. A., Romanus, D., Stull, D. M. & Hungria, V., 05.2019, In: FUTURE ONCOL. 15, 13, p. 1411-1428 18 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  24. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US

    Davies, F., Rifkin, R., Costello, C., Morgan, G., Usmani, S., Abonour, R., Palumbo, A., Romanus, D., Hajek, R., Terpos, E., Cherepanov, D., Stull, D. M., Huang, H., Leleu, X., Berdeja, J., Lee, H. C., Weisel, K., Thompson, M., Boccadoro, M., Zonder, J., Cook, G., Puig, N., Vela-Ojeda, J., Farrelly, E., Raju, A., Blazer, M. & Chari, A., 09.2021, In: ANN HEMATOL. 100, 9, p. 2325-2337 13 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  25. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

    Davies, F. E., Pawlyn, C., Usmani, S. Z., San-Miguel, J. F., Einsele, H., Boyle, E. M., Corre, J., Auclair, D., Cho, H. J., Lonial, S., Sonneveld, P., Stewart, A. K., Bergsagel, P. L., Kaiser, M. F., Weisel, K., Keats, J. J., Mikhael, J. R., Morgan, K. E., Ghobrial, I. M., Orlowski, R. Z., Landgren, C. O., Gay, F., Caers, J., Chng, W. J., Chari, A., Walker, B. A., Kumar, S. K., Costa, L. J., Anderson, K. C. & Morgan, G. J., 06.07.2022, In: BLOOD CANCER DISCOV. 3, 4, p. 273-284 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  26. A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure

    Davies, F. E., Leleu, X., Vogel, P., Dhanasiri, S., Le Nouveau, P. & Weisel, K., 11.2023, In: CL LYMPH MYELOM LEUK. 23, 11, p. 829-837.e1

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  27. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

    Dimopoulos, M. A., Gay, F., Schjesvold, F., Beksac, M., Hajek, R., Weisel, K. C., Goldschmidt, H., Maisnar, V., Moreau, P., Min, C. K., Pluta, A., Chng, W-J., Kaiser, M., Zweegman, S., Mateos, M-V., Spencer, A., Iida, S., Morgan, G., Suryanarayan, K., Teng, Z., Skacel, T., Palumbo, A., Dash, A. B., Gupta, N., Labotka, R., Rajkumar, S. V. & TOURMALINE-MM3 study group, 19.01.2019, In: LANCET. 393, 10168, p. 253-264 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  28. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial

    Dimopoulos, M. A., Lonial, S., Betts, K. A., Chen, C., Zichlin, M. L., Brun, A., Signorovitch, J. E., Makenbaeva, D., Mekan, S., Sy, O., Weisel, K. & Richardson, P. G., 15.10.2018, In: CANCER-AM CANCER SOC. 124, 20, p. 4032-4043 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  29. Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial

    Dimopoulos, M., Weisel, K., van de Donk, N. W. C. J., Ramasamy, K., Gamberi, B., Streetly, M., Offidani, M., Bridoux, F., de la Rubia, J., Mateos, M-V., Ardizzoia, A., Kueenburg, E., Collins, S., Di Micco, A., Rosettani, B., Li, Y., Bacon, P. & Sonneveld, P., 10.07.2018, In: J CLIN ONCOL. 36, 20, p. 2035-2043 9 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  30. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

    Dimopoulos, M. A., Goldschmidt, H., Niesvizky, R., Joshua, D., Chng, W-J., Oriol, A., Orlowski, R. Z., Ludwig, H., Facon, T., Hajek, R., Weisel, K., Hungria, V., Minuk, L., Feng, S., Zahlten-Kumeli, A., Kimball, A. S. & Moreau, P., 10.2017, In: LANCET ONCOL. 18, 10, p. 1327-1337 11 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  31. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

    Dimopoulos, M. A., Palumbo, A., Corradini, P., Cavo, M., Delforge, M., Di Raimondo, F., Weisel, K. C., Oriol, A., Hansson, M., Vacca, A., Blanchard, M. J., Goldschmidt, H., Doyen, C., Kaiser, M., Petrini, M., Anttila, P., Cafro, A. M., Raymakers, R., San-Miguel, J., de Arriba, F., Knop, S., Röllig, C., Ocio, E. M., Morgan, G., Miller, N., Simcock, M., Peluso, T., Herring, J., Sternas, L., Zaki, M. H. & Moreau, P., 28.07.2016, In: BLOOD. 128, 4, p. 497-503 7 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  32. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

    Dimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hájek, R., Facon, T., Ludwig, H., Oriol, A., Goldschmidt, H., Rosiñol, L., Straub, J., Suvorov, A., Araujo, C., Rimashevskaya, E., Pika, T., Gaidano, G., Weisel, K., Goranova-Marinova, V., Schwarer, A., Minuk, L., Masszi, T., Karamanesht, I., Offidani, M., Hungria, V., Spencer, A., Orlowski, R. Z., Gillenwater, H. H., Mohamed, N., Feng, S., Chng, W-J. & ENDEAVOR Investigators, 01.2016, In: LANCET ONCOL. 17, 1, p. 27-38 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  33. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone

    Dimopoulos, M. A., Weisel, K. C., Song, K. W., Delforge, M., Karlin, L., Goldschmidt, H., Moreau, P., Banos, A., Oriol, A., Garderet, L., Cavo, M., Ivanova, V., Alegre, A., Martinez-Lopez, J., Chen, C., Spencer, A., Knop, S., Bahlis, N. J., Renner, C., Yu, X., Hong, K., Sternas, L., Jacques, C., Zaki, M. H. & San Miguel, J. F., 10.2015, In: HAEMATOLOGICA. 100, 10, p. 1327-33 7 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  34. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

    Dimopoulos, M. A., Leleu, X., Palumbo, A., Moreau, P., Delforge, M., Cavo, M., Ludwig, H., Morgan, G. J., Davies, F. E., Sonneveld, P., Schey, S. A., Zweegman, S., Hansson, M., Weisel, K., Mateos, M. V., Facon, T. & Miguel, J. F. S., 08.2014, In: LEUKEMIA. 28, 8, p. 1573-85 13 p.

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  35. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma

    Dimopoulos, M. A., Jakubowiak, A. J., McCarthy, P. L., Orlowski, R. Z., Attal, M., Bladé, J., Goldschmidt, H., Weisel, K. C., Ramasamy, K., Zweegman, S., Spencer, A., Huang, J. S. Y., Lu, J., Sunami, K., Iida, S., Chng, W-J., Holstein, S. A., Rocci, A., Skacel, T., Labotka, R., Palumbo, A. & Anderson, K. C., 13.02.2020, In: BLOOD CANCER J. 10, 2, p. 17

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  36. Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis

    Dimopoulos, M. A., Niesvizky, R., Weisel, K., Siegel, D. S., Hajek, R., Mateos, M-V., Cavo, M., Huang, M., Zahlten-Kumeli, A. & Moreau, P., 09.03.2020, In: BLOOD CANCER J. 10, 3, p. 35

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  37. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

    Dimopoulos, M., Quach, H., Mateos, M-V., Landgren, O., Leleu, X., Siegel, D., Weisel, K., Yang, H., Klippel, Z., Zahlten-Kumeli, A. & Usmani, S. Z., 18.07.2020, In: LANCET. 396, 10245, p. 186-197 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  38. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

    Dimopoulos, M. A., Lonial, S., White, D., Moreau, P., Weisel, K., San-Miguel, J., Shpilberg, O., Grosicki, S., Špička, I., Walter-Croneck, A., Magen, H., Mateos, M-V., Belch, A., Reece, D., Beksac, M., Spencer, A., Oakervee, H., Orlowski, R. Z., Taniwaki, M., Röllig, C., Einsele, H., Matsumoto, M., Wu, K. L., Anderson, K. C., Jou, Y-M., Ganetsky, A., Singhal, A. K. & Richardson, P. G., 04.09.2020, In: BLOOD CANCER J. 10, 9, p. 91

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  39. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

    Dimopoulos, M., Weisel, K., Moreau, P., Anderson, L. D., White, D., San-Miguel, J., Sonneveld, P., Engelhardt, M., Jenner, M., Corso, A., Dürig, J., Pavic, M., Salomo, M., Casal, E., Srinivasan, S., Yu, X., Nguyen, T. V., Biyukov, T., Peluso, T. & Richardson, P., 06.2021, In: LEUKEMIA. 35, 6, p. 1722-1731 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  40. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

    Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., Magen, H., Larocca, A., Laubach, J. P., Petrucci, M. T., Reece, D., White, D., Mateos, M-V., Špička, I., Lazaroiu, M., Berdeja, J., Kaufman, J. L., Jou, Y-M., Ganetsky, A., Popa McKiver, M., Lonial, S., Weisel, K. & ELOQUENT-1 investigators, 06.2022, In: LANCET HAEMATOL. 9, 6, p. e403-e414

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  41. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

    Dimopoulos, M. A., Merlini, G., Bridoux, F., Leung, N., Mikhael, J., Harrison, S. J., Kastritis, E., Garderet, L., Gozzetti, A., van de Donk, N. W. C. J., Weisel, K. C., Badros, A. Z., Beksac, M., Hillengass, J., Mohty, M., Ho, P. J., Ntanasis-Stathopoulos, I., Mateos, M-V., Richardson, P., Blade, J., Moreau, P., San-Miguel, J., Munshi, N., Rajkumar, S. V., Durie, B. G. M., Ludwig, H., Terpos, E. & International Myeloma Working Group, 07.2023, In: LANCET ONCOL. 24, 7, p. e293-e311

    Research output: SCORING: Contribution to journalSCORING: Review articleResearch

  42. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study

    Dimopoulos, M. A., Hungria, V. T. M., Radinoff, A., Delimpasi, S., Mikala, G., Masszi, T., Li, J., Capra, M., Maiolino, A., Pappa, V., Chraniuk, D., Osipov, I., Leleu, X., Low, M., Matsumoto, M., Sule, N., Li, M., McKeown, A., He, W., Bright, S., Currie, B., Perera, S., Boyle, J., Roy-Ghanta, S., Opalinska, J. & Weisel, K., 10.2023, In: LANCET HAEMATOL. 10, 10, p. e801-e812

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  43. Paraneoplastic granulocyte colony-stimulating factor secretion in soft tissue sarcoma mimicking myeloproliferative neoplasia: a case report

    Dorn, C., Bugl, S., Malenke, E., Müller, M. R., Weisel, K. C., Vogel, U., Horger, M., Kanz, L. & Kopp, H-G., 23.05.2014, In: BMC RES NOTES. 7, p. 313

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  44. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

    D'Souza, A., Shah, N., Rodriguez, C., Voorhees, P. M., Weisel, K., Bueno, O. F., Pothacamury, R. K., Freise, K. J., Yue, S., Ross, J. A., Polepally, A. R., Talati, C., Lee, S., Jin, Z., Buelow, B., Vij, R. & Kumar, S., 01.11.2022, In: J CLIN ONCOL. 40, 31, p. 3576-3586 11 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  45. Cutaneous presentation of hematological malignancies

    Eberle, F. C., Metzler, G., Weisel, K. C., Berneburg, M. & Yazdi, A. S., 21.06.2013, In: EUR J DERMATOL. 23, 3, p. 372-7 6 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  46. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

    Einsele, H., Moreau, P., Bahlis, N., Bhutani, M., Vincent, L., Karlin, L., Perrot, A., Goldschmidt, H., van de Donk, N. W. C. J., Ocio, E. M., Martinez-Lopez, J., Rodríguez-Otero, P., Dytfeld, D., Diels, J., Strulev, V., Haddad, I., Renaud, T., Ammann, E., Cabrieto, J., Perualila, N., Gan, R., Zhang, Y., Parekh, T., Albrecht, C., Weisel, K. & Mateos, M-V., 04.2024, In: ADV THER. 41, 4, p. 1576-1593 18 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  47. RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma

    Emde-Rajaratnam, M., Beck, S., Benes, V., Salwender, H., Bertsch, U., Scheid, C., Hänel, M., Weisel, K., Hielscher, T., Raab, M. S., Goldschmidt, H., Jauch, A., Maes, K., De Bruyne, E., Menu, E., De Veirman, K., Moreaux, J., Vanderkerken, K., Seckinger, A. & Hose, D., 2023, In: FRONT IMMUNOL. 14, p. 1286700

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  48. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

    Facon, T., Dimopoulos, M. A., Dispenzieri, A., Catalano, J. V., Belch, A., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N. J., Banos, A., Tiab, M., Delforge, M., Cavenagh, J. D., Geraldes, C., Lee, J-J., Chen, C., Oriol, A., De La Rubia, J., White, D., Binder, D., Lu, J., Anderson, K. C., Moreau, P., Attal, M., Perrot, A., Arnulf, B., Qiu, L., Roussel, M., Boyle, E., Manier, S., Mohty, M., Avet-Loiseau, H., Leleu, X., Ervin-Haynes, A., Chen, G., Houck, V., Benboubker, L. & Hulin, C., 18.01.2018, In: BLOOD. 131, 3, p. 301-310 10 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  49. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

    Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., O'Dwyer, M., Perrot, A., Venner, C. P., Weisel, K., Mace, J. R., Raje, N., Attal, M., Tiab, M., Macro, M., Frenzel, L., Leleu, X., Ahmadi, T., Chiu, C., Wang, J., Van Rampelbergh, R., Uhlar, C. M., Kobos, R., Qi, M., Usmani, S. Z. & MAIA Trial Investigators, 30.05.2019, In: NEW ENGL J MED. 380, 22, p. 2104-2115 12 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Previous 1 2 3 4 5 Next